These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20545782)

  • 1. CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.
    Seresini S; Origoni M; Caputo L; Lillo F; Longhi R; Vantini S; Paganoni AM; Protti MP
    Immunology; 2010 Sep; 131(1):89-98. PubMed ID: 20545782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer.
    Santin AD; Hermonat PL; Ravaggi A; Chiriva-Internati M; Zhan D; Pecorelli S; Parham GP; Cannon MJ
    J Virol; 1999 Jul; 73(7):5402-10. PubMed ID: 10364287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6.
    de Jong A; van Poelgeest MI; van der Hulst JM; Drijfhout JW; Fleuren GJ; Melief CJ; Kenter G; Offringa R; van der Burg SH
    Cancer Res; 2004 Aug; 64(15):5449-55. PubMed ID: 15289354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia.
    Bontkes HJ; de Gruijl TD; van den Muysenberg AJ; Verheijen RH; Stukart MJ; Meijer CJ; Scheper RJ; Stacey SN; Duggan-Keen MF; Stern PL; Man S; Borysiewicz LK; Walboomers JM
    Int J Cancer; 2000 Oct; 88(1):92-8. PubMed ID: 10962445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFN-gamma produced by human papilloma virus-18 E6-specific CD4+ T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions.
    Seresini S; Origoni M; Lillo F; Caputo L; Paganoni AM; Vantini S; Longhi R; Taccagni G; Ferrari A; Doglioni C; Secchi P; Protti MP
    J Immunol; 2007 Nov; 179(10):7176-83. PubMed ID: 17982110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.
    de Gruijl TD; Bontkes HJ; Stukart MJ; Walboomers JM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
    J Gen Virol; 1996 Sep; 77 ( Pt 9)():2183-91. PubMed ID: 8811018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia.
    Kadish AS; Ho GY; Burk RD; Wang Y; Romney SL; Ledwidge R; Angeletti RH
    J Natl Cancer Inst; 1997 Sep; 89(17):1285-93. PubMed ID: 9293919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of E6 and E7 levels in high-risk HPV16 type cervical lesions with CCL20 and Langerhans cells.
    Jiang B; Xue M
    Genet Mol Res; 2015 Sep; 14(3):10473-81. PubMed ID: 26400278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
    Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
    Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease.
    Welters MJ; van der Logt P; van den Eeden SJ; Kwappenberg KM; Drijfhout JW; Fleuren GJ; Kenter GG; Melief CJ; van der Burg SH; Offringa R
    Int J Cancer; 2006 Feb; 118(4):950-6. PubMed ID: 16152582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
    Mizuuchi M; Hirohashi Y; Torigoe T; Kuroda T; Yasuda K; Shimizu Y; Saito T; Sato N
    Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
    Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend.
    Kim KH; Greenfield WW; Cannon MJ; Coleman HN; Spencer HJ; Nakagawa M
    Cancer Immunol Immunother; 2012 Jan; 61(1):63-70. PubMed ID: 21842207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: correlation with presence of papillomavirus DNA.
    Rosales R; López-Contreras M; Cortes RR
    J Med Virol; 2001 Dec; 65(4):736-44. PubMed ID: 11745939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years.
    Paaso A; Koskimaa HM; Welters MJ; Grénman S; Syrjänen K; van der Burg SH; Syrjänen S
    J Transl Med; 2015 May; 13():163. PubMed ID: 25990808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer.
    Nindl I; Rindfleisch K; Lotz B; Schneider A; Dürst M
    Int J Cancer; 1999 Jul; 82(2):203-7. PubMed ID: 10389753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia.
    Zumbach K; Kisseljov F; Sacharova O; Shaichaev G; Semjonova L; Pavlova L; Pawlita M
    Int J Cancer; 2000 Feb; 85(3):313-8. PubMed ID: 10652419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer.
    Chan PK; Liu SJ; Cheung JL; Cheung TH; Yeo W; Chong P; Man S
    J Med Virol; 2011 Jun; 83(6):1023-30. PubMed ID: 21503915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.
    Chan PK; Liu SJ; Cheung TH; Yeo W; Ngai SM; Cheung JL; Chong P; Man S
    Clin Vaccine Immunol; 2010 Sep; 17(9):1315-21. PubMed ID: 20668141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.